Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Puma Biotechnology, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of targeted cancer therapies. The company operates within the oncology segment of the biotechnology and pharmaceutical industries, with an emphasis on small-molecule drugs that inhibit key signaling pathways involved in tumor growth. Its primary revenue is derived from the commercialization of its lead oncology product, which is approved for specific indications in breast cancer.
The company’s core product is NERLYNX® (neratinib), an oral, irreversible pan-HER tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer. Puma Biotechnology primarily serves oncologists, hospitals, and specialty pharmacies, targeting patients in both early-stage and metastatic breast cancer settings. Founded in 2010, the company evolved from a clinical-stage developer into a commercial-stage biopharmaceutical firm following U.S. regulatory approval of NERLYNX® in 2017, marking a significant transition in its business model toward commercialization and lifecycle management.
Business Operations
Puma Biotechnology operates as a single-reportable segment focused on oncology drug development and commercialization. The company generates revenue primarily from product sales of NERLYNX® in the United States and select international markets through distribution and licensing arrangements. Commercial activities include sales, marketing, medical affairs, and post-marketing clinical studies, while research and development efforts continue to support label expansion and combination therapy studies.
The company does not maintain large-scale manufacturing facilities and instead relies on third-party contract manufacturers for the production of its drug products. International operations are conducted through partnerships and sublicensing agreements, particularly in Europe and Asia, which allow Puma Biotechnology to extend market reach while limiting direct operational infrastructure. No material joint ventures have been publicly disclosed beyond these regional licensing relationships.
Strategic Position & Investments
Puma Biotechnology’s strategic direction centers on maximizing the clinical and commercial value of NERLYNX® through expanded indications, combination regimens, and geographic expansion. Growth initiatives have included continued investment in clinical trials evaluating neratinib in combination with other therapies, particularly in HER2-mutated cancers beyond breast cancer. The company’s strategy emphasizes disciplined capital allocation, given its reliance on a single marketed product.
Historically, Puma Biotechnology expanded its pipeline through acquisitions of development-stage assets, including the acquisition of Neratinib rights prior to regulatory approval, which remains the cornerstone of its portfolio. While the company maintains an oncology-focused research pipeline, publicly available information indicates that the majority of investment remains concentrated on lifecycle management rather than diversification into unrelated therapeutic areas. Data inconclusive based on available public sources regarding any material late-stage pipeline assets beyond neratinib.
Geographic Footprint
Puma Biotechnology is headquartered in Los Angeles, California, and its primary commercial presence is in the United States, which represents the majority of its revenue. The company has established a market presence in Europe, Asia, and Latin America through licensing and distribution partners, enabling international sales without direct large-scale operations in those regions.
International influence is primarily commercial rather than manufacturing-based, with regulatory approvals and reimbursement processes managed by regional partners. The company does not report significant physical infrastructure outside the United States, and its global footprint is characterized by a partner-driven model designed to optimize reach while controlling operating costs.
Leadership & Governance
Puma Biotechnology was founded by industry executives with experience in oncology drug development, and its leadership team emphasizes scientific rigor, regulatory compliance, and focused execution around its core asset. The company’s governance structure aligns with public biotechnology peers, with oversight provided by an independent board of directors and management compensation linked to clinical and commercial performance.
Key executives include:
- Alan H. Auerbach – Founder, President, and Chief Executive Officer
- Michael C. Warner – Chief Financial Officer
- Steven S. Rosenberg – Chief Operating Officer
- Susan C. Pendergrass – Executive Vice President, Regulatory Affairs
- Michael J. Miller – Executive Vice President, Research and Development
Leadership has consistently articulated a strategy centered on disciplined growth, prudent expense management, and long-term value creation through oncology-focused innovation.